Get the Stockscreener App
1.29
3.73%
-0.05
After Hours:
1.33
0.04
+3.10%
Fate Therapeutics Inc stock is traded at $1.29, with a volume of 1.42M.
It is down -3.73% in the last 24 hours and up +10.26% over the past month.
Fate Therapeutics Inc is a clinical-stage biopharmaceutical company based in the United States. The company is engaged in the development of programmed cellular immunotherapies for cancer and autoimmune disorders. The company's cell therapy pipeline is comprised of NK- and T-cell immuno-oncology programs, including off-the-shelf engineered product candidates derived from clonal master iPSC lines, and immuno-regulatory programs, including product candidates to prevent life-threatening complications in patients.
See More
Previous Close:
$1.34
Open:
$1.34
24h Volume:
1.42M
Relative Volume:
0.89
Market Cap:
$149.98M
Revenue:
$6.65M
Net Income/Loss:
$-136.32M
P/E Ratio:
-1.124
EPS:
-1.1477
Net Cash Flow:
$-112.04M
1W Performance:
+9.32%
1M Performance:
+10.26%
6M Performance:
-15.69%
1Y Performance:
+15.18%
1-Day Range:
$1.26
$1.36
1-Week Range:
$1.18
$1.45
52-Week Range:
$0.91
$1.9399
Fate Therapeutics Inc Stock (FATE) Company Profile
Name
Fate Therapeutics Inc
Sector
Industry
Phone
858.875.1803
Address
12278 SCRIPPS SUMMIT DRIVE, SAN DIEGO, CA
Compare FATE vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
FATE
Fate Therapeutics Inc
|
1.29 | 155.79M | 6.65M | -136.32M | -112.04M | -1.1477 |
VRTX
Vertex Pharmaceuticals Inc
|
441.70 | 113.01B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
753.93 | 79.87B | 14.34B | 4.50B | 3.77B | 41.56 |
ARGX
Argen X Se Adr
|
840.87 | 51.51B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
333.39 | 45.29B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
319.94 | 34.41B | 5.36B | 287.73M | 924.18M | 2.5229 |
Fate Therapeutics Inc Stock (FATE) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Oct-31-25 | Upgrade | H.C. Wainwright | Neutral → Buy |
| Oct-27-25 | Upgrade | Wedbush | Neutral → Outperform |
| Nov-18-24 | Upgrade | BofA Securities | Underperform → Neutral |
| Jun-17-24 | Upgrade | Piper Sandler | Neutral → Overweight |
| Mar-27-23 | Resumed | Wells Fargo | Equal Weight |
| Jan-24-23 | Downgrade | H.C. Wainwright | Buy → Neutral |
| Jan-06-23 | Downgrade | BMO Capital Markets | Outperform → Market Perform |
| Jan-06-23 | Downgrade | BofA Securities | Buy → Underperform |
| Jan-06-23 | Downgrade | Cowen | Outperform → Market Perform |
| Jan-06-23 | Downgrade | Piper Sandler | Overweight → Neutral |
| Jan-06-23 | Downgrade | Stifel | Buy → Hold |
| Jan-06-23 | Downgrade | Truist | Buy → Hold |
| Jan-06-23 | Downgrade | Wedbush | Outperform → Neutral |
| Jan-03-23 | Downgrade | Guggenheim | Buy → Neutral |
| Dec-22-22 | Downgrade | Oppenheimer | Outperform → Perform |
| Dec-15-22 | Initiated | Goldman | Sell |
| Nov-04-22 | Resumed | Cantor Fitzgerald | Overweight |
| Oct-10-22 | Initiated | Canaccord Genuity | Buy |
| Aug-18-22 | Resumed | Wells Fargo | Overweight |
| Jul-28-22 | Initiated | Needham | Hold |
| Jul-11-22 | Upgrade | BMO Capital Markets | Market Perform → Outperform |
| Jun-03-22 | Initiated | Robert W. Baird | Neutral |
| Feb-11-22 | Resumed | BMO Capital Markets | Market Perform |
| Dec-15-21 | Upgrade | Wedbush | Neutral → Outperform |
| Dec-07-21 | Initiated | Cowen | Outperform |
| Nov-09-21 | Upgrade | Citigroup | Neutral → Buy |
| Aug-26-21 | Initiated | Morgan Stanley | Equal-Weight |
| Jun-07-21 | Upgrade | H.C. Wainwright | Neutral → Buy |
| May-07-21 | Upgrade | Wedbush | Neutral → Outperform |
| Apr-26-21 | Resumed | Jefferies | Buy |
| Feb-26-21 | Initiated | BofA Securities | Buy |
| Feb-26-21 | Downgrade | Wedbush | Outperform → Neutral |
| Feb-11-21 | Downgrade | Citigroup | Buy → Neutral |
| Jan-27-21 | Resumed | H.C. Wainwright | Neutral |
| May-13-20 | Initiated | H.C. Wainwright | Buy |
| Mar-04-20 | Initiated | Barclays | Overweight |
| Jan-09-20 | Downgrade | BMO Capital Markets | Outperform → Market Perform |
| Dec-30-19 | Reiterated | Mizuho | Buy |
| Dec-09-19 | Upgrade | Wells Fargo | Market Perform → Outperform |
| Nov-12-19 | Initiated | SunTrust | Buy |
| Nov-06-19 | Downgrade | Wells Fargo | Outperform → Market Perform |
| Oct-01-19 | Initiated | Stifel | Buy |
| Aug-09-19 | Initiated | BTIG Research | Buy |
| Jul-22-19 | Initiated | Cantor Fitzgerald | Overweight |
| Jul-12-19 | Initiated | Oppenheimer | Outperform |
| Jun-13-19 | Initiated | Mizuho | Buy |
| Jun-07-19 | Initiated | ROTH Capital | Neutral |
| May-31-19 | Initiated | Guggenheim | Buy |
| May-24-19 | Resumed | Citigroup | Buy |
| Mar-28-19 | Initiated | SVB Leerink | Outperform |
| Jan-03-19 | Downgrade | Stephens | Overweight → Equal-Weight |
| Nov-05-18 | Initiated | Jefferies | Buy |
| Aug-01-18 | Initiated | Citigroup | Buy |
| Mar-06-18 | Downgrade | H.C. Wainwright | Buy → Neutral |
View All
Fate Therapeutics Inc Stock (FATE) Latest News
Aug Wrap: Is Fate Therapeutics Inc part of any ETFDay Trade & Daily Stock Trend Reports - baoquankhu1.vn
Fate Therapeutics Inc stock (US3025491025): Is its iPSC platform strong enough to unlock biotech ups - AD HOC NEWS
Fate Therapeutics Inc stock: Q2 2026 conferences signal active engagement - AD HOC NEWS
Fate Therapeutics to Participate in Upcoming Second Quarter 2026 Conferences - GlobeNewswire
Fate Therapeutics reports new employee inducement award under Nasdaq listing rule 5635(c)(4) - marketscreener.com
Fate Therapeutics Announces New Employee Inducement Award - National Today
Fate Therapeutics Reports New Employee Inducement Award Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Fate Therapeutics Inc (F6T.DU) Stock Price, News, Quote & History - Yahoo! Finance Canada
Street Watch: Is Fate Therapeutics Inc subject to activist investor interest2026 Rallies & Weekly Breakout Watchlists - baoquankhu1.vn
FATE Should I Buy - Intellectia AI
Fate Therapeutics Inc Stock: Pioneering iPSC Cell Therapies Amid Biotech Volatility - AD HOC NEWS
Fate Therapeutics (NASDAQ:FATE) Share Price Passes Below 200-Day Moving AverageHere's What Happened - MarketBeat
Scalable Biotech Manufacturing Unlocks a $14B Market - Benzinga
Scalable Biotech Manufacturing Unlocks a $14B Market - Sahm
Vanguard (FATE) reports 0 shares after internal realignment - Stock Titan
Mizuho reiterates Fate Therapeutics stock rating on trial progress By Investing.com - Investing.com Canada
Fate Therapeutics, Inc. (NASDAQ:FATE) Receives Consensus Recommendation of "Hold" from Brokerages - MarketBeat
Take Profit: Will Fate Therapeutics Inc outperform small cap indexes2026 Volatility Report & Long Hold Capital Preservation Tips - baoquankhu1.vn
Fate Therapeutics Inc stock faces analyst caution amid biotech pipeline scrutiny - AD HOC NEWS
The $45 Billion Cell Therapy Boom Just Hit a Manufacturing Milestone Most Investors Haven’t Noticed - marketscreener.com
FATE Stock Price, Quote & Chart | FATE THERAPEUTICS INC (NASDAQ:FATE) - ChartMill
Fate Therapeutics, Inc. (NASDAQ:FATE) Short Interest Down 14.1% in February - MarketBeat
Big Picture: Can Fate Therapeutics Inc beat the S P 5002026 Intraday Action & Trade Opportunity Analysis Reports - baoquankhu1.vn
FATE SEC FilingsFate Therapeutic 10-K, 10-Q, 8-K Forms - Stock Titan
Fate Therapeutics Details FT819 CAR T Manufacturing and Phase II Lupus Trial Plans at Conference - MarketBeat
Performance Recap: Can Fate Therapeutics Inc ride the EV waveProduct Launch & Consistent Profit Focused Trading Strategies - baoquankhu1.vn
Lessons From Bringing A Novel T Cell Class For Autoimmune Diseases Into The Clinic - Clinical Leader
Valuation Update: Can Fate Therapeutics Inc lead its sector in growthWeekly Trading Summary & AI Powered Market Entry Strategies - baoquankhu1.vn
Fate Therapeutics (FATE) Reports Q2 Loss, Beats Revenue Estimates - MSN
Fate Therapeutics at Leerink Global Healthcare Conference: Strategic Shift in Focus - Investing.com Canada
FATE: FT819 shows promising efficacy and safety in lupus nephritis, with pivotal trials set for later this year - TradingView
Dividend Watch: Can Fate Therapeutics Inc. ride the EV waveCEO Change & Risk Controlled Daily Trade Plans - baoquankhu1.vn
CEO Change: Can Fate Therapeutics Inc keep up with sector leaders2026 Bull vs Bear & Long-Term Capital Growth Strategies - baoquankhu1.vn
Fate Therapeutics Forms Golden Cross, Signaling Potential Bullish Breakout - Markets Mojo
Risk Analysis: Can Fate Therapeutics Inc lead its sector in growthJuly 2025 Big Picture & Expert Approved Momentum Trade Ideas - baoquankhu1.vn
Fed Meeting: Can Fate Therapeutics Inc beat the S P 5002025 Technical Patterns & Free Expert Verified Stock Movement Alerts - baoquankhu1.vn
Bull Bear: Can Fate Therapeutics Inc lead its sector in growthFed Meeting & Fast Entry and Exit Trade Plans - baoquankhu1.vn
The Pipeline for iPSC-Derived Cell Therapeutics in 2026 - BioInformant
Fate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire
New Fate Therapeutics hires get 50,700 stock units over 4 years - Stock Titan
Fate Therapeutics to Participate in Leerink Partners 2026 Global Healthcare Conference - GlobeNewswire
FATE Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
Growth Value: Is Fate Therapeutics Inc subject to activist investor interestQuarterly Market Summary & High Return Trade Opportunity Guides - baoquankhu1.vn
Analysts Offer Insights on Healthcare Companies: BioCryst (BCRX) and Fate Therapeutics (FATE) - The Globe and Mail
Fate Therapeutics (NASDAQ:FATE) Posts Earnings Results, Meets Expectations - MarketBeat
Fate Therapeutics Inc expected to post a loss of 28 cents a shareEarnings Preview - TradingView
Baird reiterates Fate Therapeutics stock rating on trial progress By Investing.com - Investing.com Canada
Fate Therapeutics (FATE) Reports Q4 Loss, Misses Revenue Estimates - Yahoo Finance
Fate Therapeutics earnings beat, revenue topped estimates By Investing.com - Investing.com UK
Fate Therapeutics: Fourth Quarter Earnings Overview - Bitget
Biotechnology company Fate Therapeutics Inc announced that its current cash reserves are sufficient to sustain company operations until the end of 2027. - Bitget
Fate Therapeutics Inc Stock (FATE) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.69%
0.25%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):